Peng-Jun Lu1, Mei-Chuan Hung2, Anup Srivastav2, Walter W Williams3, Kathleen L Dooling4. 1. Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia. Electronic address: plu@cdc.gov. 2. Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; Leidos Inc., Atlanta, Georgia. 3. Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia. 4. Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Abstract
INTRODUCTION: In 2006, zoster vaccine live was recommended for adults aged ≥60 years. In 2011, zoster vaccine live was approved for use but not recommended for adults aged 50-59 years. This study assessed zoster vaccine live coverage among adults aged 50-59 years and ≥60 years. METHODS: Data from the 2013-2017 National Health Interview Surveys were analyzed in 2019 to estimate national zoster vaccine live coverage among adults aged ≥50 years. State-specific zoster vaccine live coverage among adults aged ≥50 years was assessed using 2017 Behavioral Risk Factor Surveillance System data. RESULTS: Among adults aged 50-59 years, zoster vaccine live coverage was 5.7% in 2017, ranging from 4% to 6% during 2013-2017 (test for trend, p>0.05). Zoster vaccine live coverage among adults aged 50-59 years ranged from 5.8% in Pennsylvania to 14.7% in South Dakota. By 2017, zoster vaccine live was received by 34.9% of adults aged ≥60 years, a significant increase from 24.2% in 2013. Zoster vaccine live coverage among adults aged ≥60 years in 2017 ranged from 26.0% in Mississippi to 51.8% in Vermont. In 2017, major characteristics significantly associated with increased likelihood of zoster vaccine live vaccination among adults aged 50-59 years and ≥60 years were older age, having 4 to 9 physician contacts in the past 12 months, and having a usual place for health care. CONCLUSIONS: This study provides an assessment of zoster vaccine live coverage among adults aged ≥50 years before the newly recommended recombinant zoster vaccine came into widespread use. Providers should routinely assess adults' vaccination status and strongly recommend or offer needed vaccines to their patients. Published by Elsevier Inc.
INTRODUCTION: In 2006, zoster vaccine live was recommended for adults aged ≥60 years. In 2011, zoster vaccine live was approved for use but not recommended for adults aged 50-59 years. This study assessed zoster vaccine live coverage among adults aged 50-59 years and ≥60 years. METHODS: Data from the 2013-2017 National Health Interview Surveys were analyzed in 2019 to estimate national zoster vaccine live coverage among adults aged ≥50 years. State-specific zoster vaccine live coverage among adults aged ≥50 years was assessed using 2017 Behavioral Risk Factor Surveillance System data. RESULTS: Among adults aged 50-59 years, zoster vaccine live coverage was 5.7% in 2017, ranging from 4% to 6% during 2013-2017 (test for trend, p>0.05). Zoster vaccine live coverage among adults aged 50-59 years ranged from 5.8% in Pennsylvania to 14.7% in South Dakota. By 2017, zoster vaccine live was received by 34.9% of adults aged ≥60 years, a significant increase from 24.2% in 2013. Zoster vaccine live coverage among adults aged ≥60 years in 2017 ranged from 26.0% in Mississippi to 51.8% in Vermont. In 2017, major characteristics significantly associated with increased likelihood of zoster vaccine live vaccination among adults aged 50-59 years and ≥60 years were older age, having 4 to 9 physician contacts in the past 12 months, and having a usual place for health care. CONCLUSIONS: This study provides an assessment of zoster vaccine live coverage among adults aged ≥50 years before the newly recommended recombinant zoster vaccine came into widespread use. Providers should routinely assess adults' vaccination status and strongly recommend or offer needed vaccines to their patients. Published by Elsevier Inc.
Authors: Michael W Link; Indu B Ahluwalia; Gary L Euler; Carolyn B Bridges; Susan Y Chu; Pascale M Wortley Journal: Am J Epidemiol Date: 2006-01-27 Impact factor: 4.897
Authors: Doug Campos-Outcalt; Michelle Jeffcott-Pera; Pamela Carter-Smith; Bellinda K Schoof; Herbert F Young Journal: Ann Fam Med Date: 2010 Nov-Dec Impact factor: 5.166
Authors: Barbara P Yawn; Patricia Saddier; Peter C Wollan; Jennifer L St Sauver; Marge J Kurland; Lina S Sy Journal: Mayo Clin Proc Date: 2007-11 Impact factor: 7.616
Authors: Junling Wang; Lindsay J Ford; La'Marcus Wingate; Sarah Frank Uroza; Nina Jaber; Cindy T Smith; Richard Randolph; Steve Lane; Stephan L Foster Journal: J Am Pharm Assoc (2003) Date: 2013 Jan-Feb
Authors: Ryan R Thompson; Christina L Kong; Travis C Porco; Eric Kim; Caleb D Ebert; Nisha R Acharya Journal: Clin Infect Dis Date: 2021-11-02 Impact factor: 9.079
Authors: Jeffrey F Scherrer; Joanne Salas; Timothy L Wiemken; Daniel F Hoft; Christine Jacobs; John E Morley Journal: PLoS One Date: 2021-11-17 Impact factor: 3.240
Authors: Timothy L Wiemken; Joanne Salas; John E Morley; Daniel F Hoft; Christine Jacobs; Jeffrey F Scherrer Journal: J Am Geriatr Soc Date: 2021-12-12 Impact factor: 7.538